Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915925 · ClinicalTrials.gov registry record
Short-term Clinical Deterioration After Acute Pulmonary Embolism
A clinical trial of Pulmonary Embolism, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 935
- Enrollment target
- 6
- Study locations
NCT03915925: Completed study of Pulmonary Embolism, sponsored by Wake Forest University Health Sciences.
NCT03915925 is a study of Pulmonary Embolism that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 935 participants, below the 3,039-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (69% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03915925, a study of Pulmonary Embolism, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 935 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a prospective, observational, multicenter cohort study to compare right ventricular dysfunction dependent and independent prognostic models for short-term serous adverse events in patients who are diagnosed with pulmonary embolism in the emergency department. Clinical endpoints are assessed at days 1-5. A thirty-day follow-up phone call is conducted to obtain further clinical endpoints and a quality of life assessment.
Primary Outcome
Provide and compare the number and proportion of patients with both composite and individual outcome of death, circulatory deterioration, respiratory deterioration, administration of reperfusion therapy
Conditions Studied
Study Locations (6)
California
- San Diego Medical Center - San Diego
Delaware
- Christiana Care Health System - Newark
Florida
- Orlando Regional Medical Center - Orlando
North Carolina
- Carolinas Medical Center - Main - Charlotte
Tennessee
- Vanderbilt Medical Center - Nashville
Utah
- Univeristy of Utah Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 935 participants |
| Start Date | 2018-09-30 |
| Est. Completion | 2020-11-30 |
What the finished NCT03915925 record still lists
NCT03915925 is an observational study that tracks outcomes without assigning an intervention. The registered 935 participants enrollment target is mid-sized for trials with a published cap, below the 3,039-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 0 interventions.
NCT03915925 lists 6 locations in 6 states (California, Delaware, Florida).
Frequently Asked Questions
What is clinical trial NCT03915925 about?
NCT03915925 is a clinical study titled "Short-term Clinical Deterioration After Acute Pulmonary Embolism". This is a prospective, observational, multicenter cohort study to compare right ventricular dysfunction dependent and independent prognostic models for short-term serous adverse events in patients who are diagnosed with pulmonary embolism in the emergency department. Clinical endpoints are assessed ...
What is the current status of trial NCT03915925?
This trial is currently completed. The enrollment target is 935 participants. The study started on 2018-09-30. Estimated completion is 2020-11-30.
What conditions does trial NCT03915925 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
Who is sponsoring clinical trial NCT03915925?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915925 being conducted?
This trial has 6 study locations across California, Delaware, Florida, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03915925's enrollment target sits among peer trials
935 9th of 48 higher than 40 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
The PERSEVERE Study
RECRUITING · NA
-
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
RECRUITING
-
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI